CTMX
CytomX Therapeutics, Inc.Company with tickers: CTMX
CIK
1501989
CUSIP
23284F105
Shares Outstanding
217,702,919
Price History
Institutional Holders
Short Volume
Short Interest
Fails to Deliver
Financials
SEC Filings
Earnings Calls
Insider Trades
Congressional Trades
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | $10,258,000 | USD | 2026-03-31 | 10-Q | 2026-05-07 |
| Revenue (ASC 606) | $10,258,000 | USD | 2026-03-31 | 10-Q | 2026-05-07 |
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | $29,930,000 | USD | 2026-03-31 | 10-Q | 2026-05-07 |
| Research & Development | $19,238,000 | USD | 2026-03-31 | 10-Q | 2026-05-07 |
| Operating Income | $-19,672,000 | USD | 2026-03-31 | 10-Q | 2026-05-07 |
| Net Income | $-18,248,000 | USD | 2026-03-31 | 10-Q | 2026-05-07 |
| EPS (Basic) | — | ||||
| EPS (Diluted) | — |